Two new studies show how immunotherapies collaborate to boost T cell responses in melanoma.

Two new studies conducted by researchers at the University of Pittsburgh have revealed how immunotherapies targeting the immune checkpoints PD1 and LAG3 work together to activate immune responses in melanoma patients. The studies found that combination therapies targeting both checkpoints can improve outcomes compared to monotherapies targeting only PD1. The researchers analyzed data from a human clinical trial and animal models to investigate the responses of tumor-killing CD8+ T cells. The findings provide insights into the mechanisms behind combination therapies and offer opportunities for further clinical development. [Extracted from the article]